Pericarditis clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Showing trials for
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
Sorry, not currently recruiting here
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 14 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients who discontinue therapy with an IL-1 blocker for recurrent pericarditis remain free of pericarditis recurrence while receiving CardiolRx.
Irvine, California and other locations
Last updated: